2,000 Shares in Electromed, Inc. (NYSE:ELMD) Bought by IFP Advisors Inc

IFP Advisors Inc acquired a new stake in Electromed, Inc. (NYSE:ELMD) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 2,000 shares of the company’s stock, valued at approximately $59,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ELMD. State Street Corp grew its position in Electromed by 14.5% in the third quarter. State Street Corp now owns 22,066 shares of the company’s stock valued at $474,000 after acquiring an additional 2,800 shares during the period. Pekin Hardy Strauss Inc. grew its holdings in shares of Electromed by 9.9% in the 3rd quarter. Pekin Hardy Strauss Inc. now owns 38,185 shares of the company’s stock worth $820,000 after purchasing an additional 3,435 shares during the last quarter. Legacy Wealth Asset Management LLC acquired a new stake in shares of Electromed during the 4th quarter worth about $253,000. Barclays PLC acquired a new stake in shares of Electromed during the 3rd quarter worth about $215,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in Electromed in the third quarter valued at about $226,000. 40.82% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ELMD. StockNews.com lowered Electromed from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. B. Riley began coverage on Electromed in a research note on Thursday, February 20th. They issued a “buy” rating and a $38.00 target price for the company.

Electromed Stock Down 4.9 %

ELMD stock opened at $24.71 on Friday. Electromed, Inc. has a twelve month low of $13.74 and a twelve month high of $35.56. The company has a market cap of $211.44 million, a P/E ratio of 32.95 and a beta of 0.33. The business’s fifty day moving average is $31.14 and its 200-day moving average is $26.00.

Insider Activity

In other news, Director Kathleen Skarvan sold 38,954 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $29.28, for a total value of $1,140,573.12. Following the completion of the transaction, the director now owns 32,622 shares of the company’s stock, valued at $955,172.16. The trade was a 54.42 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Andrew Summers sold 35,273 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $28.83, for a total value of $1,016,920.59. Following the sale, the director now directly owns 129,190 shares in the company, valued at $3,724,547.70. The trade was a 21.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 133,618 shares of company stock valued at $3,821,636 in the last ninety days. 14.00% of the stock is owned by insiders.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.